- CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022
- CHF4.6M equity financing in July extends cash runway into Q2 2023
- Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q1 2023
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 18, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the periods ended June 30, 2022 and provided a corporate update.
“The recent financing from Armistice Capital and the extension of our strategic collaboration with Indivior have set us on a solid path to execute on our strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer, CEO of Addex. “In addition, we are looking forward to the data read-out from the ADX71149 epilepsy Phase 2 study in Q1 2023 and continue to evaluate the path forward for dipraglurant in a number of interesting disease areas in parallel to discussions with potential strategic partners.”
H2 2022 Operating Highlights:
- ADX71149 epilepsy Phase 2 study on track to report data in Q1 2023
- Terminated dipraglurant Phase 2b/3 study in dyskinesia associated with Parkinson’s disease
- Reported results from dipraglurant Phase 2 study in blepharospasm patients
- GABAB PAM strategic partnership with Indivior for substance use disorders extended – multiple…
